JP2024528986A5 - - Google Patents
Info
- Publication number
- JP2024528986A5 JP2024528986A5 JP2024506668A JP2024506668A JP2024528986A5 JP 2024528986 A5 JP2024528986 A5 JP 2024528986A5 JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024528986 A5 JP2024528986 A5 JP 2024528986A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- nitrogen
- sulfur
- oxygen
- partially unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203890P | 2021-08-03 | 2021-08-03 | |
| US63/203,890 | 2021-08-03 | ||
| US202163264749P | 2021-12-01 | 2021-12-01 | |
| US63/264,749 | 2021-12-01 | ||
| PCT/US2022/074455 WO2023015199A1 (en) | 2021-08-03 | 2022-08-03 | Hpk1 antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528986A JP2024528986A (ja) | 2024-08-01 |
| JP2024528986A5 true JP2024528986A5 (enExample) | 2025-08-13 |
Family
ID=85156431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506668A Pending JP2024528986A (ja) | 2021-08-03 | 2022-08-03 | Ｈｐｋ１アンタゴニスト及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250011331A1 (enExample) |
| EP (1) | EP4380565A4 (enExample) |
| JP (1) | JP2024528986A (enExample) |
| WO (1) | WO2023015199A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240153578A (ko) * | 2022-02-23 | 2024-10-23 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 피롤리논 함유 융합 비시클릭 화합물 |
| US20250361241A1 (en) * | 2022-06-10 | 2025-11-27 | Betta Pharmaceuticals Co., Ltd. | Hpk1 inhibitor and medical use thereof |
| WO2024078448A1 (zh) * | 2022-10-10 | 2024-04-18 | 珠海宇繁生物科技有限责任公司 | 一种hpk1激酶抑制剂及其制备方法和应用 |
| WO2025021181A1 (zh) * | 2023-07-26 | 2025-01-30 | 正大天晴药业集团股份有限公司 | 取代的吡咯啉酮化合物 |
| WO2025096666A1 (en) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Solid forms of hpk1 antagonists |
| WO2026072991A1 (en) * | 2024-09-26 | 2026-04-02 | Arvinas Operations, Inc. | Hpk1 targeting compounds and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| KR101846475B1 (ko) * | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| MA42456B1 (fr) * | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
| CN110402248B (zh) * | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| EP3707138B1 (en) * | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| US11142525B2 (en) * | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| EP3972695A1 (en) * | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| MX2022002877A (es) * | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
| WO2021262684A1 (en) * | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
-
2022
- 2022-08-03 WO PCT/US2022/074455 patent/WO2023015199A1/en not_active Ceased
- 2022-08-03 EP EP22854068.8A patent/EP4380565A4/en active Pending
- 2022-08-03 JP JP2024506668A patent/JP2024528986A/ja active Pending
- 2022-08-03 US US18/294,922 patent/US20250011331A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024528986A5 (enExample) | ||
| JP2021527126A5 (enExample) | ||
| JP2022547719A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP7258748B2 (ja) | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2021523225A5 (enExample) | ||
| RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2024506909A5 (enExample) | ||
| JP2023552827A5 (enExample) | ||
| JP2022509260A5 (enExample) | ||
| JP2009518296A5 (enExample) | ||
| JP2023515620A5 (enExample) | ||
| JP2023515621A5 (enExample) | ||
| JP2011515337A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2017537940A (ja) | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 | |
| JP2023506410A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| JP2022514385A5 (enExample) | ||
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| RU2016119519A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2017537940A5 (enExample) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| CN107249593A (zh) | 调节染色质结构的组合物用于移植物抗宿主疾病(gvhd)的用途 |